<DOC>
	<DOCNO>NCT00022464</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness CCI-779 treating patient metastatic melanoma .</brief_summary>
	<brief_title>CCI-779 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine anti-tumor activity CCI-779 , term progression-free survival , patient metastatic melanoma . - Determine toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive CCI-779 IV 30 minute day 1 . Courses repeat every 7 day absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : Approximately 40-50 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic melanoma incurable surgery , radiotherapy , limb perfusion Measurable disease At least 20 mm conventional technique OR At least 10 mm spiral CT scan The following consider measurable : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Progressive disease No prior concurrent CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 4 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST ALT great 2.5 time upper limit normal Cholesterol great 350 mg/dL ( lipidlowering therapy allow ) Triglycerides great 300 mg/dL except hydroxymethylglutarylcoenzyme A reductase inhibitor Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No prior allergic reaction compound similar chemical biological composition study drug No ongoing active infection No seizure disorder No autoimmune disease No psychiatric illness social situation would preclude study No concurrent uncontrolled illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior adjuvant biological therapy regimen No 1 prior biological therapy regimen advance disease At least 6 month since prior biological therapy biochemotherapy recover Prior isolate limb perfusion biological agent allow sole site disease Chemotherapy : See Biologic therapy Prior isolated limb perfusion chemotherapy allow sole site disease No 1 prior chemotherapycontaining regimen advance disease , regardless adjuvant therapy May addition 1 prior biologic regimen advance disease OR May 1 prior biochemotherapy regimen advance disease At least 3 week since prior chemotherapy recover Endocrine therapy : At least 1 week since prior dexamethasone No concurrent glucocorticosteroid therapy Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : At least 1 week since prior phenobarbital , phenytoin , carbamazepine , rifampin At least 3 week since prior agent treat malignancy At least 3 week since prior investigational agent No concurrent investigational agent No concurrent drug metabolize alter level cytochrome P4503A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>